Advances and challenges in targeting FGFR signalling in cancer

By I. Babina, N. Turner. Nature Reviews. Cancer, 2017

718 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e55807094959c9d24d8092e6cfef80d048a1a088

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Huanhuan Chen
2. Li-li Zheng
3. Zhenling Liu
4. Li-Ping Sun
5. Lei Shi

Citations in the corpus

• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Moreover, these FGFR inhibitors inhibits cell proliferation in FGFR-addicted cancer cells with FGFR aberrations such as gene amplification, activating mutations and chromosomal translocations.(465)”
• Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “Different types of genetic alterations in FGF receptor amplification, mutations, and gene-fusion have been shown to respond variably to certain drugs, and hence demand molecular profiling for the selection of effective drugs.(46,197) Another promising example is of using poly ADP ribose polymerase (”